Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes

Abstract

Background:

Insulin glargine 300 U/mL (Gla-300) has a more constant and prolonged action profile than insulin glargine 100 U/mL and in clinical studies is associated with similar glycemic control but less hypoglycemia. Whether its effects are altered by variability of injection time was examined in two 3-month substudies.

Materials and Methods:

Eligible participants completing 6 months of optimized treatment with Gla-300 in EDITION 1 (n = 109) and EDITION 2 (n = 89), having a mean hemoglobin A1c (HbA_1c) level of 7.3 % (SD 1.0 %), were randomized (1:1) to groups advised to increase variability of between-injection intervals to 24 ± up to 3 h or to maintain fixed 24-h intervals for 3 months. Changes of HbA_1c level and other efficacy and safety measures were assessed.

Results:

In the fixed-dosing group, 64% of participants reported all intervals within the 23–25-h range, compared with 15% of those advised flexible dosing. In the fixed- and flexible-dosing groups, 12% and 41%, respectively, of between-injection intervals were outside the 23–25-h range, and 2% and 16%, respectively, were outside the 21–27-h range. Least squares mean between-group difference in HbA_1c change from baseline was 0.05 % (95% confidence interval [CI], −0.13 to 0.23); for fasting plasma glucose, 2.7 mg/dL (95% CI, −9.0 to 14.4); and for daily basal insulin dose, 0.00 U/kg (95% CI, −0.02 to 0.03). Frequencies of hypoglycemia and adverse events did not differ between groups.

Conclusions:

The efficacy and safety of Gla-300 demonstrated in EDITION 1 and EDITION 2 are maintained in substudies when the insulin was injected up to 3 h before or after the usual time of administration.